Company news
Cynata Therapeutics Limited (ASX:CYP) news
Cynata Therapeutics Limited news releases on 6ix. Latest, Oct 7, 2026: Cynata Receives R&D TI Refund & Repays R&D TI Loan
Press releases & updates
Cynata Receives R&D TI Refund & Repays R&D TI Loan
October 6, 2026
R&D Tax Incentive Loan Facility Extension
September 29, 2026
Notification under Listing Rule 4.3D
September 23, 2026
Appendix 4E & Preliminary Final Report
August 30, 2026
June 2026 Quarterly Activity Report & Appendix 4C
July 29, 2026
Board, Management Changes, Expenditure Reductions, RDTI Loan
July 5, 2026
Reinstatement to Official Quotation
June 18, 2026
CYP-001 GvHD Trial Primary Evaluation Results
June 16, 2026
Suspension from Quotation
June 15, 2026
EU Positive Opinion on CYP-001 Paediatric Investigation Plan
June 2, 2026
Cynata Secures Commitments for $1.5m Placement
May 3, 2026
March 2026 Quarterly Activity Report & Appendix 4C
April 30, 2026
Last Visit in GvHD Trial Completed
March 29, 2026
Appendix 4D & Half-Year Financial Statements
February 26, 2026
December 2025 Quarterly Activity Report and Appendix 4C
January 28, 2026
Cynata Completes $1.2m At-The-Market Raise
January 23, 2026
Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
December 14, 2025
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
December 14, 2025
Positive DSMB Review in Phase 1/2 Kidney Transplant Trial
December 3, 2025
Final Patient Visit Complete in Phase 3 Osteoarthritis Trial
November 23, 2025
Cynata Receives $1.7m R&D Tax Incentive Refund
November 5, 2025
September 2025 Quarterly Activity Report and Appendix 4C
October 31, 2025
Appendix 4E & Annual Report
August 28, 2025
At-the-Market Subscription Agreement
August 21, 2025
June 2025 Quarterly Activity Report and Appendix 4C
July 30, 2025
CYP-001s FDA Approval Pathway Not Impeded
May 16, 2025
March 2025 Quarterly Activity Report and Appendix 4C
April 24, 2025
Publication comparing Cymerus MSCs to other MSCs
February 4, 2025
Quarterly Activity Report & Appendix 4C
January 29, 2025
First Kidney Transplant Trial Patient Treated
December 11, 2024
Cynata secures commitments for $8.1m institutional placement
December 5, 2024
Demonstrated Safety & Efficacy in DFU Clinical Trial
December 5, 2024
Trading Halt
December 3, 2024
Cynata Receives $1.88m R&D Tax Incentive Refund
November 26, 2024
Study of Cymerus MSCs in Pulmonary Fibrosis Published
August 8, 2024
Cynata to Acquire IP from Tekcyte
July 1, 2024
Further GvHD Clinical Data Published in Nature Medicine
May 22, 2024
DFU Clinical Trial Enrolment Complete
April 7, 2024
EU Approval for Phase 2 CYP-001 Trial in GvHD
March 19, 2024
First Patient Treated in Phase 2 GvHD Trial
March 4, 2024
Encouraging Initial Data from CYP-006TK DFU Trial
February 25, 2024
Recruitment Completed in Phase 3 OA Clinical Trial
December 12, 2023
Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey
December 6, 2023
Cynata Receives $2.315m R&D Tax Incentive Refund
November 13, 2023
Approval of Clinical Trial of CYP-001 in Kidney Transplant
August 20, 2023
Phase 2 Trial of CYP-001 in aGvHD Open for Recruitment
August 9, 2023
Strategic Review of Cynata Clinical Development Portfolio
July 24, 2023
Cynata announces CEO succession and Board changes
June 29, 2023
Cynata Completes Oversubscribed Share Purchase Plan
May 10, 2023
Share Purchase Plan Booklet & Option Prospectus
April 19, 2023